JP2013538856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538856A5 JP2013538856A5 JP2013531769A JP2013531769A JP2013538856A5 JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5 JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- pharmaceutical composition
- composition according
- pegylated
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38900910P | 2010-10-01 | 2010-10-01 | |
| US61/389,009 | 2010-10-01 | ||
| PCT/US2011/053681 WO2012044684A2 (en) | 2010-10-01 | 2011-09-28 | Interferon-beta for use as monotherapy or in combination with other cancer therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181104A Division JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013538856A JP2013538856A (ja) | 2013-10-17 |
| JP2013538856A5 true JP2013538856A5 (enExample) | 2014-11-13 |
Family
ID=45890011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531769A Pending JP2013538856A (ja) | 2010-10-01 | 2011-09-28 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
| JP2016181104A Pending JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016181104A Pending JP2017025086A (ja) | 2010-10-01 | 2016-09-16 | 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120082647A1 (enExample) |
| EP (1) | EP2621516B1 (enExample) |
| JP (2) | JP2013538856A (enExample) |
| AU (2) | AU2011308906B2 (enExample) |
| CA (1) | CA2813304A1 (enExample) |
| ES (1) | ES2587837T3 (enExample) |
| MX (1) | MX2013003599A (enExample) |
| NZ (2) | NZ705124A (enExample) |
| WO (1) | WO2012044684A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| EP2958584A1 (en) | 2013-02-20 | 2015-12-30 | Yeda Research and Development Co., Ltd. | Interferon treatment targeting mutant p53 expressing cells |
| WO2014130811A1 (en) * | 2013-02-22 | 2014-08-28 | Biogen Idec Ma Inc | Interferon beta formulation |
| ES2736503T3 (es) * | 2014-04-04 | 2020-01-02 | Ares Trading Sa | Nuevos análogos de la proteína IFN beta |
| CN107427492B (zh) * | 2014-11-19 | 2021-03-26 | 查岱龙 | 用于治疗癌症的医药组合物、其方法及筛选药物的生物标记 |
| KR102666000B1 (ko) * | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
| CN112569358B (zh) * | 2019-09-30 | 2022-06-28 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用 |
| CN121197419A (zh) * | 2019-09-30 | 2025-12-26 | 上海生物制品研究所有限责任公司 | 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| PL174772B1 (pl) | 1993-01-06 | 1998-09-30 | Kinerton Ltd | Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy |
| DK1656952T3 (da) * | 1998-10-16 | 2014-01-20 | Biogen Idec Inc | Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf |
| WO2004020468A2 (en) * | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
| GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| US20070105887A1 (en) * | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
| BRPI0816769A2 (pt) * | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
-
2011
- 2011-09-28 US US13/247,556 patent/US20120082647A1/en not_active Abandoned
- 2011-09-28 MX MX2013003599A patent/MX2013003599A/es unknown
- 2011-09-28 NZ NZ705124A patent/NZ705124A/en not_active IP Right Cessation
- 2011-09-28 ES ES11829825.6T patent/ES2587837T3/es active Active
- 2011-09-28 WO PCT/US2011/053681 patent/WO2012044684A2/en not_active Ceased
- 2011-09-28 CA CA2813304A patent/CA2813304A1/en not_active Abandoned
- 2011-09-28 AU AU2011308906A patent/AU2011308906B2/en not_active Ceased
- 2011-09-28 JP JP2013531769A patent/JP2013538856A/ja active Pending
- 2011-09-28 NZ NZ608630A patent/NZ608630A/en not_active IP Right Cessation
- 2011-09-28 EP EP11829825.6A patent/EP2621516B1/en not_active Not-in-force
-
2015
- 2015-10-15 US US14/884,530 patent/US20160228513A1/en not_active Abandoned
-
2016
- 2016-09-15 AU AU2016228234A patent/AU2016228234A1/en not_active Abandoned
- 2016-09-16 JP JP2016181104A patent/JP2017025086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077356A (es) | Forma termodinámicamente estable de una sal tosilato | |
| JP2012502885A5 (enExample) | ||
| MX2009002642A (es) | 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluoro fenoxi]-n-metilpiridina-2-carboxamida monohidrato. | |
| UA100966C2 (ru) | Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей | |
| BR112013026706A2 (pt) | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico | |
| JP2012520883A5 (enExample) | ||
| JP2011510093A5 (ja) | 口腔ケア製品ならびにその使用および製造の方法 | |
| JP2009517473A5 (enExample) | ||
| PT2684877T (pt) | Sal farmaceuticamente aceitável de (e)-n-[4-[[3-cloro-4-(2- piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2r)-1-metilpirrolidin-2-il]prop-2-enamida, seu método de preparação e a sua utilização clínica | |
| EP2724707A3 (de) | Haarpflegemittel mit Antischuppenwirkstoffen und einem kationischen Keratinhydrolysat | |
| NZ596863A (en) | Alkanoylamino benzamide aniline hdac inhibitor compounds | |
| TWI351950B (en) | Use of (halobenzyloxy) benzylamino-propanamides fo | |
| TW200718700A (en) | Novel isoindole derivatives, compositions containing them, preparation thereof and pharmaceutical uses thereof, in particular as inhibitors of the activities of the HSP90 chaperone protein | |
| NO20064050L (no) | Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient | |
| JP2011068692A5 (enExample) | ||
| CN103655242B (zh) | 水解小麦蛋白洗发露 | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| SG143203A1 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome | |
| CY1111257T1 (el) | Χρηση της αγομελατινης για τη ληψη φαρμακων προοριζομενων για τη θεραπεια των διπολικων διαταραχων | |
| JP2015509917A5 (enExample) | ||
| CL2007003216A1 (es) | Sal de 2(s), 4(s), 5(s), 7(s)-n-(3-amino-2,2-dimetil-3-oxo-propil)2,7-di(1-metil-etil)-4-hidroxi-5-amino-8-[4-metoxi-3-(3-metoxi-propoxi)fenil]-octanamida; proceso de preparacion; composicion farmaceutica; y uso para la profilaxis o tratamiento de en | |
| JP2008513348A5 (enExample) | ||
| CO6592037A2 (es) | Combinación de un aine y un aminoacido | |
| EA201201286A1 (ru) | Новое биологически активное соединение n-[3-(нитрофениламино)индол-2-илметилен]аминогуанидина гидрохлорид с противовоспалительной активностью | |
| NO20064048L (no) | Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den |